Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,537,214,304 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under ...

Study Results - The IRAKLIA phase 3 study demonstrated that the subcutaneous (SC) formulation of Sarclisa, administered via an on-body delivery system (OBDS) in combination with pomalidomide and dexamethasone (Pd), met its co-primary endpoints of non-inferior objective response rate (ORR) and observed concentration before dosing (C trough) at steady state compared to intravenous (IV) Sarclisa in patients with relapsed or refractory multiple myeloma (R/R MM) [1] - Key secondary endpoints, including very good partial response (VGPR), incidence rate of infusion reactions, and C trough at cycle 2, were also achieved [1] - The study enrolled 531 patients across 252 global sites, with patients randomized to receive either SC or IV Sarclisa in combination with Pd for 28-day cycles until disease progression or other discontinuation criteria were met [4] Subcutaneous Formulation and OBDS - The SC formulation of Sarclisa, delivered via the enFuse OBDS, represents a potential new administration option for patients, offering comparable efficacy and safety to the IV formulation [2] - The enFuse OBDS, developed by Enable Injections, is designed to administer high-volume medicines subcutaneously through an automated drug delivery technology, featuring a hidden and retractable needle that is thinner than commonly used SC injection needles [2][7] - The IRAKLIA study is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDS, aiming to improve the patient experience and reduce time spent in healthcare facilities [5] Regulatory and Clinical Development - Regulatory submissions for the SC formulation of Sarclisa are planned in the US and EU during the first half of 2025 [3] - Additional studies evaluating Sarclisa SC formulations across different combinations and lines of therapy are ongoing, with the safety and efficacy of the SC formulation and enFuse device yet to be evaluated by regulatory authorities outside of their approved indications [3][8] About Sarclisa - Sarclisa (isatuximab) is a CD38 monoclonal antibody that targets MM cells through multiple mechanisms of action, including apoptosis and immunomodulatory activity [8] - Currently approved in more than 50 countries, Sarclisa is indicated for the treatment of R/R MM in combination with Pd or carfilzomib and dexamethasone, and as a front-line treatment option for newly diagnosed MM in combination with VRd [8] Sanofi's Strategic Focus - Sanofi is committed to advancing oncology innovation, with a focus on difficult-to-treat cancers such as multiple myeloma, acute myeloid leukemia, and certain lymphomas, as well as gastrointestinal and lung cancers [9] - The company continues to advance Sarclisa as part of a patient-centric clinical development program, with several phase 2 and phase 3 studies across the MM treatment continuum [8][9]

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory discussionsProgram underscores Sanofi's Immunology leadership ambitio ...

Availability of the Q4 2024 Aide-mémoire Paris, France – December 17, 2024. Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website: Fourth quarter & full year 2024 results (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. ...

Santander’s fully digital bank, Openbank, launched in Mexico on Tuesday (Nov. 19).The Openbank Mexico website and app are now operating, promising a fully digital bank, no minimum balances, no fees and competitive interest rates, Openbank said in a Tuesday press release.Customers can also access 24/7 telephone support and all 10,000 Santander Mexico ATMs, according to the release.“Openbank Mexico is now a reality for all Mexicans who want to manage their finances quickly, easily, 100% digitally, and with th ...

Long-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics and future price action. Instead, our articles focus on operational aspects, understanding the long-term earnings power of companies, the competitive dynamics of the industries where they participate, and buying companies that we would like to hold independently of how the price moves in the future. Most QC calls will be holds, and that is by design. Only a very sm ...

It's time for me to provide my quarterly update for Banco Santander, S.A. (NYSE: SAN ). Since I last wrote about the bank, we're only up around 3%, with the S&P 500 up around 5%. But I look at the return sinceAnalyst’s Disclosure: I/we have a beneficial long position in the shares of SAN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relati ...

Core Insights - Santander has officially launched its digital banking platform, Openbank, in the United States, marking a significant expansion of its consumer banking operations beyond the Northeast [1] - Openbank features a streamlined onboarding process that can be completed in as little as five minutes through its app or website, enhancing customer experience and reducing operational costs [1] - The launch of Openbank is part of Santander's broader growth strategy to roll out additional banking products in the U.S. by 2025, aiming to provide a full suite of banking services similar to its offerings in Europe [2] Company Strategy - Banco Santander's Executive Chairman, Ana Botín, emphasized the importance of deploying proprietary core and front-end cloud-based technology globally to achieve a sustainable competitive advantage [2] - Openbank aims to offer the best high-yield savings accounts in America, characterized by simplicity, speed, and competitive rates [2] - The launch of Openbank is expected to accelerate Santander's execution of its growth strategy in the U.S., generating deposits to support its leading auto franchise [2] Customer Experience - Openbank is described as one of the most advanced digital banks in Europe, with a focus on providing U.S. customers a superior digital-first service that is fast, simple, and accessible anytime, anywhere [3] - The platform aims to enhance customer experience through a user-friendly interface integrated with core banking infrastructure [1][3] Recent Developments - Santander Consumer has recently expanded its small business offerings to all auto dealers using its platform, allowing small business owners to finance vehicles through its consumer banking division [3]

[Item 1 Report of Other Relevant Information dated September 30, 2024](index=3&type=section&id=Item%201%20Report%20of%20Other%20Relevant%20Information%20dated%20September%2030%2C%202024) This report outlines Banco Santander's tender offer results for Senior Non-Preferred and Senior Preferred Instruments, along with contact information, legal disclaimers, and signatory details [Tender Offer Details and Results](index=3&type=section&id=Tender%20Offer%20Details%20and%20Results) Banco Santander announced the results of its tender offer for EUR SNP and EUR SP Notes, with significant principal amounts accepted and cancelled - Banco Santander invited holders of its outstanding **€1,500,000,000 1.375% Senior Non-Preferred Instruments due January 2026** and **€1,750,000,000 3.750% Fixed Rate Senior Preferred Instruments due January 2026** to tender any and all such Notes for purchase for cash[5](index=5&type=chunk) - The Expiration Time for the Offers was **5:00 p.m. (CET) on September 27, 2024**[6](index=6&type=chunk) Tender Offer Accepted Amounts and Prices | Description of Notes | Aggregate principal amount accepted (€) | Purchase Price (%) | Accrued Interest Amount (€) | | :----------------------------------------------------------------------- | :---------------------------------- | :----------------------------------------- | :---------------------- | | €1,500,000,000 1.375 per cent. Senior Non-Preferred Instruments due January 2026 | 502,700,000 | 98.297 | 5,117,988.70 | | €1,750,000,000 3.750 per cent. Fixed Rate Senior Preferred Instruments due January 2026 | 713,700,000 | 101.360 | 19,012,468.41 | - Notes purchased by the Offeror pursuant to the Offer will be **cancelled** and will not be re-issued or re-sold[8](index=8&type=chunk) Outstanding Nominal Amounts Following Settlement | Note Type | Outstanding Nominal Amount (Following Settlement Date) (€) | | :-------- | :--------------------------------------------------- | | EUR SNP Notes | 997,300,000 | | EUR SP Notes | 1,036,300,000 | - Payment of the relevant Tender Consideration for accepted Notes is expected to occur on the **Settlement Date, October 2, 2024**[9](index=9&type=chunk) [Contact Information for Offers](index=3&type=section&id=Contact%20Information%20for%20Offers) Contact details for the Sole Dealer Manager and Tender Agent are provided for inquiries regarding the tender offers - The Sole Dealer Manager for the offers is **Santander Corporate and Investment Banking**, located at Ciudad Grupo Santander, Madrid, Spain[11](index=11&type=chunk) - The Tender Agent is **Kroll Issuer Services Limited**, located at The Shard, London, United Kingdom[11](index=11&type=chunk) [Legal Disclaimers](index=5&type=section&id=Legal%20Disclaimers) This announcement includes important disclaimers regarding its distribution and advises qualifying holders to seek independent professional advice - This announcement is not for release, publication, or distribution in or into or to any person located or resident in any jurisdiction where or to whom it is unlawful to do so[12](index=12&type=chunk) - The announcement must be read in conjunction with the **Tender Offer Memorandum**, which contains important information[14](index=14&type=chunk) - Qualifying Holders are recommended to seek their own financial, legal, regulatory, and tax advice immediately from a professional adviser if in doubt about the contents or actions to take[14](index=14&type=chunk) [Signature](index=6&type=section&id=Signature) The report is formally signed on behalf of Banco Santander, S.A. by an authorized signatory - The report was signed on **September 30, 2024**[16](index=16&type=chunk) - The signatory is **Pedro de Mingo Kaminouchi**, Head of Regulatory Compliance for Banco Santander, S.A.[16](index=16&type=chunk)

Investors interested in Banks - Foreign stocks are likely familiar with Banco Santander (SAN) and National Australia Bank Ltd. (NABZY) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision tr ...